---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-051371"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:49:00.167054+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences appoints Steve Hoerter to board of directors

## Summary
- Steven L. Hoerter appointed as independent director effective April 7, 2025.
- Board expanded from 8 to 9 members; Hoerter designated as Class III director until 2027 AGM.
- Hoerter is former CEO of Deciphera Pharmaceuticals (acquired by Ono for $2.4B in 2024).
- Brings 30+ years pharma commercialization experience; also serves on boards of ORIC Pharmaceuticals and C4 Therapeutics.
- Will receive standard non-employee director compensation and enter indemnification agreement.

## SEC filing metadata
- accession: 0000950170-25-051371
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/0000950170-25-051371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/mbx-20250407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-051371
- JSON: https://secwatch.observer/filing/0000950170-25-051371.json
- Plain text: https://secwatch.observer/filing/0000950170-25-051371.txt

## Key facts
- Executive change
  Steven L. Hoerter was appointed as director at MBX Biosciences, Inc..
  - Action: appointed
  - Role: director
  source text: Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1776111/000095017025051371/0000950170-25-051371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.